Delivered her PhD thesis "Treatment response evaluation in experimental prostate cancer by functional magnetic resonance imaging and molecular profiling" in 2012.
Skingen VE, Salberg UB, Hompland T, Fjeldbo CS, Helgeland H, Frikstad KM, Ragnum HB, Vlatkovic L, Hole KH, Seierstad T, Lyng H(2024) Spatial analysis of microRNA regulation at defined tumor hypoxia levels reveals biological traits of aggressive prostate cancer J Pathol, 264(3), 270-283 DOI 10.1002/path.6344, PubMed 39329425
Fernandez Salamanca M, Hompland T, Deręgowska-Cylke M, Van der Poel H, Bekers E, Guimaraes MAS, Lyng H, Van der Heide UA, Schoots IG, Van Houdt PJ(2024) A DWI-based hypoxia model shows robustness in an external prostatectomy cohort Front Oncol, 14, 1433197 DOI 10.3389/fonc.2024.1433197, PubMed 39109282
Marsilla J, Weiss J, Ye XY, Welch M, Milosevic M, Lyng H, Hompland T, Bruheim K, Tadic T, Haibe-Kains B, Han K(2024) A T2-weighted MRI-based radiomic signature for disease-free survival in locally advanced cervical cancer following chemoradiation: An international, multicentre study Radiother Oncol, 199, 110463 DOI 10.1016/j.radonc.2024.110463, PubMed 39067707
Heidi Lyng, Department of Radiation Biology, Institute for Cancer Research Norwegian Radium Hospital, Oslo University Hospital Phone +47 22 78 1478, e-mail: heidi.lyng@rr-research.no
